fludarabine has been researched along with Acute Disease in 137 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (16.06) | 18.2507 |
| 2000's | 73 (53.28) | 29.6817 |
| 2010's | 31 (22.63) | 24.3611 |
| 2020's | 11 (8.03) | 2.80 |
| Authors | Studies |
|---|---|
| Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| Arat, M; Berceanu, A; Giebel, S; Hamladji, RM; Kröger, N; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Potter, V; Rambaldi, A; Sanz, J; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R; Yakoub-Agha, I | 1 |
| Arat, M; Bourhis, JH; Cornelissen, JJ; Giebel, S; Grillo, G; Hilgendorf, I; Kröger, N; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Poiré, X; Salmenniemi, U; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R | 1 |
| Aljurf, M; Arat, M; Bourhis, JH; Brissot, E; Forcade, E; Giebel, S; Helbig, G; Huynh, A; Kröger, N; Labopin, M; Labussière-Wallet, H; Lioure, B; Mohty, M; Nagler, A; Peric, Z; Reményi, P; Salmenniemi, U; Savani, BN; Socié, G; Spirydonidis, A; Srour, M; Tbakhi, A; Zahrani, MA | 1 |
| Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M | 1 |
| Beasley, M; Castleton, A; Chakraverty, R; Diez, P; Elhanied, M; Fielding, A; Gilleece, M; Hodgkinson, A; Jackson, A; Marks, DI; Mikhaeel, G; Olavarria, E | 1 |
| Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ | 1 |
| Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M | 1 |
| Aotsuka, N; Hangaishi, A; Hoshino, T; Kako, S; Kanda, Y; Kato, J; Kobayashi, T; Matsumoto, K; Mori, T; Najima, Y; Okamoto, S; Onizuka, M; Shimizu, H; Shono, K; Tachibana, T; Tanaka, M; Tsukamoto, S; Usuki, K; Watanabe, R; Yamazaki, E; Yano, S | 1 |
| Choi, Y; Do, YR; Jung, SH; Kim, DS; Koh, Y; Lee, JH; Lee, S; Lee, SS; Lee, WS; Moon, JH; Mun, YC; Park, HS; Park, Y; Yang, DH; Yhim, HY; Yi, JH | 1 |
| Araqi Houssaini, L; Chiheb, S; Hali, F; Marnissi, F; Quessar, A | 1 |
| Ball, LM; Bresters, D; Fiocco, M; Louwerens, M; van Doorn, R; Wanders, DCM | 1 |
| Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC | 1 |
| Chan, KW; De Oliveira, S; Eapen, M; Fei, M; Hattersely, G; Horowitz, MM; Kurtzberg, J; Mendizabal, A; Schultz, KR; Wagner, JE; Wall, D; Zhang, MJ | 1 |
| Chen, Y; Feng, J; Lin, F; Lu, N; Ma, Y; Shi, Y; Sun, L; Tang, L; Wang, N; Xing, C; Yu, K | 1 |
| Bashey, A; Holland, HK; Morris, LE; Solh, M; Solomon, SR; Zhang, X | 1 |
| Arakawa, T; Hino, M; Koh, H; Nakamae, H; Nakane, T; Nishimoto, M; Ohsawa, M; Watanabe, K | 1 |
| Abrams, S; Chen, GL; Hahn, T; Liu, H; McCarthy, PL; Ross, M; Zhang, Y | 1 |
| Bachanova, V; Blazar, BR; Cooley, S; Curtsinger, J; Defor, TE; Hippen, K; Lewis, D; McGlave, P; McKenna, DH; Miller, JS; Panoskaltsis-Mortari, A; Verneris, MR; Weisdorf, DJ; Zhang, B | 1 |
| Elmore, L; Khawaja, MR; Mumaw, CL; Nelson, RP; Orschell, C; Paczesny, S; Perkins, SM | 1 |
| Abedin, S; Choi, S; Couriel, DR; Levine, JE; Peres, E; Yanik, G | 1 |
| Chen, XC; Huang, XO; Li, JJ; Liu, T; Liu, ZG; Lu, ZP; Tang, Y | 1 |
| Choi, YS; Jeon, YW; Kim, DY; Kim, HJ; Kim, JH; Kim, YJ; Lee, JH; Lee, JW; Lee, KH; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Aldenhoven, M; Bierings, MB; Boelens, JJ; Bonney, D; Borrill, RE; Coussons, M; Jones, SA; Mercer, J; van der Ploeg, AT; van Hasselt, PM; Versluys, B; Wijburg, FA; Wynn, RF | 1 |
| Davis, J; Haut, P; Hayashi, R; Kothari, A; Loechelt, BJ; Murray, L; Ngwube, A; Shenoy, S | 1 |
| Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ | 1 |
| Bhargava, S; Chakrabarti, A; Chakrabarti, S; Chatterjee, S; Jaiswal, SR; O'Donnell, P; Ray, K | 1 |
| Hong, DS; Ji, YS; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MS; Min, CW; Park, SK; Won, JH; Yun, J | 1 |
| Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ | 1 |
| Cho, BS; Cho, SG; Chung, NG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Cao, TM; Franke, GN; Gyurkocza, B; Hoppe, R; Lange, T; Leisenring, W; Maloney, DG; Negrin, RS; Sandmaier, BM; Shizuru, JA; Sorror, M; Storb, RF | 1 |
| Appelbaum, FR; Deeg, HJ; Fisher, DR; Gooley, TA; Gopal, AK; Martin, PJ; Matthews, DC; Pagel, JM; Press, OW; Rajendran, J; Sandmaier, BM; Storb, RF; Wilson, WA | 1 |
| Horiike, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M | 1 |
| Cavallin, M; Damante, G; Damiani, D; Fabbro, D; Fanin, R; Geromin, A; Malagola, M; Michelutti, A; Pianta, A; Russo, D; Tiribelli, M | 1 |
| Chakraverty, R; Denovan, S; Fielding, AK; Hough, R; Kottaridis, PD; Linch, DC; Mackinnon, S; Mead, AJ; Mohamedbhai, S; Morris, EC; Orti, G; Peggs, KS; Thomson, KJ | 1 |
| Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Palmieri, S; Riccardi, C | 1 |
| Ariga, T; Cho, Y; Ichikawa, M; Iguchi, A; Inamoto, J; Kaneda, M; Kawamura, N; Kobayashi, I; Kobayashi, R; Ohkura, Y; Ohshima, J; Sato, T; Takezaki, SI; Yamada, M | 1 |
| Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W | 1 |
| Baurmann, H; Braess, J; Buechner, T; Haferlach, C; Hahn, J; Haude, KH; Hiddemann, W; Holler, E; Kolb, HJ; Oruzio, D; Schleuning, M; Schlimok, G; Schmid, C; Schwerdtfeger, R; Spiekermann, K; Tischer, J | 1 |
| Chen, S; Du, X; Li, Y; Liu, Q; Wu, J; Wu, X; Yang, L; Zhu, K | 1 |
| Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC | 1 |
| Boudova, L; Jindra, P; Karas, M; Kazakov, D; Koza, V; Svoboda, T; Vokurka, S | 1 |
| Adams, RH; Anderlini, P; Antin, JH; Arai, S; Carter, SL; Confer, DL; Deeg, HJ; Difronzo, NL; Eapen, M; Ewell, M; Gersten, ID; Horowitz, MM; Horwitz, M; Leifer, ES; McCarty, JM; Nakamura, R; Pulsipher, MA; Tolar, J | 1 |
| Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R | 1 |
| Cook, G; Craddock, CF; Fielding, AK; Kirkland, KE; Littlewood, TJ; Marks, DI; Medd, PG; Milligan, DW; Pearce, R; Peniket, AJ; Perry, J; Potter, MN; Shaw, BE | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Aversa, F; Carotti, A; Falcinelli, F; Felicini, R; Martelli, MF; Tabilio, A; Terenzi, A; Velardi, A | 1 |
| Appelbaum, FR; Bruno, B; Chauncey, TR; Feinstein, LC; Gooley, TA; Hegenbart, U; Maloney, DG; Maris, MB; McSweeney, PA; Niederwieser, DW; Sandmaier, BM; Storb, RF | 1 |
| Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P | 1 |
| Ayash, L; Braun, T; Ferrara, JL; Hutchinson, R; Levine, JE; Ratanatharathorn, V; Reynolds, C; Silver, SM; Uberti, JP; Yanik, G | 1 |
| Robak, T | 1 |
| Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Davis, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Shen, Y; Thomas, MB; Yang, Y | 1 |
| Baker, RJ; Foroni, L; Ganeshaguru, K; Jones, DT; Mehta, AB; Mitchell, WA; Prentice, HG; Wickremasinghe, RG | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Bardou, VJ; Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Braud, AC; Cahn, JY; Chabannon, C; Choufi, B; Faucher, C; Fleury, J; François, S; Gratecos, N; Gravis, G; Maraninchi, D; Michallet, M; Mohty, M; Sotto, JJ; Viens, P; Viret, F | 1 |
| Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D | 1 |
| Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, S; Thomas, DA; Tsimberidou, AM; Verstovsek, S | 1 |
| Astrow, AB | 1 |
| Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A | 1 |
| Beelen, D; Bornhäuser, M; Ehninger, G; Fauser, AA; Held, TK; Kiehl, M; Kröger, N; Runde, V; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zabelina, T; Zander, A | 1 |
| Jackson, GH | 1 |
| Barnardo, M; Campbell, AJ; Collins, GP; Eagleton, H; Jones, J; Keen-Mcguire, A; Littlewood, TJ; Malladi, RK; Miller, E; Morgenstern, G; Norton, AE; Peniket, AJ; Samol, J | 1 |
| Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C | 1 |
| Arnold, R; Dörken, B; Heine, F; Le Coutre, P; Massenkeil, G; Nagy, M; Rosen, O | 1 |
| Broekhuizen, R; Cloos, J; Creutzig, U; Fleischhack, G; Haarman, EG; Hubeek, I; Huismans, DR; Kaspers, GJ; Litvinova, E; Peters, GJ; Zwaan, CM | 1 |
| Naito, K; Ohnishi, K | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Artz, A; Bennett, D; Cao, D; Casey, B; Daugherty, C; Del Cerro, P; Godley, L; Jones, D; Larson, RA; Odenike, O; Rich, S; Smith, S; Stock, W; Thirman, M; van Besien, K; Wickrema, A; Zimmerman, T | 1 |
| Kwong, YL; Lam, CC; Ma, ES | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Chun, K; Daly, A; Gupta, V; Hasegawa, W; Kamel-Reid, S; Kiss, T; Lipton, JH; Messner, H; Minden, M; Tsang, R; Yi, QL | 1 |
| Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Ball, ED; Bashey, A; Carrier, E; Castro, JE; Corringham, S; Hassidim, K; Holman, P; Ihasz, A; Keese, K; Lane, TA; Liu, L; Medina, B | 1 |
| Begum, G; Chopra, R; Cook, G; Cook, M; Craddock, C; Goldstone, A; Hale, G; Hunter, A; Jackson, G; Khwaja, A; Littlewood, T; Mackinnon, S; Mahendra, P; Marsh, J; Milligan, D; Parker, A; Peggs, K; Peniket, A; Russell, N; Tauro, S | 1 |
| Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A | 1 |
| Califano, C; Celentano, M; D'Amico, MR; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pollio, F | 1 |
| Bowcock, SJ; Lim, Z; Mufti, GJ; Rassam, SM; Ryali, MM; Ward, SM | 1 |
| Alexaki, P; Christakis, GB; Megalakaki, A; Perlorentzou, S; Zarkadis, IK | 1 |
| Barkholt, L; Hassan, Z; Mattsson, J; Omazic, B; Remberger, M; Ringdén, O; Sairafi, D; Uzunel, M | 1 |
| Alyea, EP; Antin, JH; Cutler, C; DeAngelo, DJ; Ho, V; Kim, HT; Ritz, J; Soiffer, RJ; Stone, R | 1 |
| Emmons, RV; Jillella, AP; Klumpp, TR; Mangan, KF; Shafer, D | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Baccarani, M; Bergonzi, C; Bocchia, M; Bonini, A; Candoni, A; Cesana, B; Damiani, D; Fanin, R; Filí, C; Geromin, A; Gobbi, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michelutti, A; Ottaviani, E; Piccaluga, PP; Pierri, I; Priccolo, G; Roccaro, AM; Russo, D; Skert, C; Testoni, N; Tiribelli, M; Visani, G; Vivo, AD; Zaccaria, A; Zuffa, E | 1 |
| Abrahamsson, J; Clausen, N; Forestier, E; Gustafsson, G; Hasle, H; Heldrup, J; Hovi, L; Jonmundsson, G; Zeller, B | 1 |
| Chuhjo, T; Kondo, Y; Kotani, T; Nakao, S; Ohtake, S; Okumura, H; Ozaki, J; Sugimori, C; Sugimori, N; Takami, A; Ueda, M; Yamaguchi, M; Yamazaki, H | 1 |
| Bardy, PG; Bradstock, KF; Gibson, J; Grigg, AP; Kennedy, G; Koelmeyer, RL; Reynolds, J; Roberts, AW; Shuttleworth, P; Szer, J; To, LB | 1 |
| Blaise, D; Faucher, C; Mohty, M; Vey, N | 1 |
| Albarello, A; Bacigalupo, A; Balleari, E; Balocco, M; Carella, AM; Catania, G; Clavio, M; Gobbi, M; Manna, A; Michelis, G; Miglino, M; Pierri, I; Sessarego, M; Van Lint, MT; Varaldo, R; Vignolo, L | 1 |
| Demidova, IA; Kut'ina, RM; Misiurin, AV; Ol'shanskaia, IuV; Parovichnikova, EN; Poreshina, LP; Savchenko, VG; Shpakova, AP | 1 |
| Baer, MR; Barcos, M; Claydon, MA; Conroy, JM; Nowak, NJ; Sait, SN | 1 |
| Grosskreutz, C; Isola, L; Osman, K; Scigliano, E | 1 |
| Bari, A; Brugiatelli, M; Buda, G; Gobbi, PG; Lazzaro, A; Lombardo, M; Luminari, S; Marcheselli, L; Marcheselli, R; Morabito, F; Pozzi, S; Quarta, G; Sacchi, S; Stelitano, C | 1 |
| Friedberg, JW | 1 |
| Hamaki, T; Hori, A; Kami, M; Kanda, Y; Katayama, Y; Kishi, Y; Kobayashi, K; Mori, S; Murashige, N; Onishi, Y; Tajima, K; Takaue, Y; Tanosaki, R | 1 |
| Escudier, SM; Seymour, JF | 1 |
| Carrara, P; Cenacchi, A; Clavio, M; Gamberi, B; Manfroi, S; Ottaviani, E; Testoni, N; Tosi, P; Visani, G; Zinzani, PL | 1 |
| Gandhi, V; Huang, P; Plunkett, W | 1 |
| Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D | 1 |
| Cannon, LM; Garfinkel, H; Pezzimenti, J; Rhodes, R; Spilove, L | 1 |
| Anderlini, P; Estey, EH; Kantarjian, HM; Keating, MJ; Luna, M; O'Brien, S; Pierce, S | 1 |
| Estey, EH; Kantarjian, HM; Keating, MA | 1 |
| Behrens, J; Killick, S; Mercieca, J; Nandi, A | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Heitjan, DF | 1 |
| Cummins, M; Deane, M; Emery, V; Gor, D; Griffith, PD; Macmahon, ME; Prentice, HG | 1 |
| Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR | 1 |
| Bertone, A; Candoni, A; Grattoni, R; Russo, D; Zaja, F | 1 |
| Ferrara, F; Latagliata, R; Magrin, S; Mele, G; Mirto, S; Montillo, M; Petti, MC; Pinto, A; Tedeschi, A; Zagonel, V | 1 |
| Du, M; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF | 1 |
| Dizdari, A; Lemoli, RM; Leopardi, G; Martinelli, G; Motta, MR; Pastano, R; Piccaluga, PP; Ricci, P; Rizzi, S; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C | 1 |
| Honma, Y; Niitsu, N; Umeda, M | 1 |
| Amurri, B; Mazza, P; Palazzo, G; Pricolo, G; Prudenzano, A; Stani, L | 1 |
| Januszewicz, EH; Juneja, S; Prince, HM; Seymour, C; Strickland, AH; Wolf, M | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Ciolli, S; Fanci, R; Leoni, F; Nozzoli, C; Rossi Ferrini , P; Santini, V | 1 |
| Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
| Bruzzone, BM; Cataldi, A; Franceschini, R; Icardi, G; Tenconi, GL | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Mohr, B; Platzbecker, U; Röllig, C; Schaich, M; Schäkel, U; Thiede, C | 1 |
| Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD | 1 |
| Dumontet, C; Galmarini, CM; Mackey, JR | 1 |
| Ariola, C; Cordone, I; Fazi, F; Fenu, S; Mandelli, F; Montefusco, E; Nanni, M; Petti, MC; Spadea, A; Spiriti, MA | 1 |
| Carella, AM; Carotenuto, M; Cascavilla, N; D'Arena, G; Greco, MM; Ladogana, S; Melillo, L; Perla, G; Sajeva, MR | 1 |
| Balleari, E; Beltrami, G; Canepa, L; Carrara, P; Cerri, R; Clavio, M; Damasio, E; Gatto, S; Ghio, R; Gobbi, M; Masoudi, B; Miglino, M; Pierri, I; Sessarego, M | 1 |
| Baccarani, M; Bertone, A; Bucalossi, A; De Vivo, A; Gobbi, M; Lauria, F; Marin, L; Mazza, P; Michelutti, A; Michieli, M; Pierri, I; Pricolo, G; Raspadori, D; Russo, D; Zaccaria, A; Zuffa, E | 1 |
| Braess, J; Büchner, T; Hiddemann, W; Kern, W; Ohnesorge, J; Schleyer, E; Unterhalt, M; Wittmer, E; Wörmann, B | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Jenke, A; Lutterbeck, K; Oelschlagel, U; Platzbecker, U; Plettig, R; Röllig, C; Thiede, C | 1 |
| Grigg, AP; Ritchie, DS; Roberts, AW; Seymour, JF; Szer, J | 1 |
| Barrett, AJ; Carter, C; Childs, R; de Witte, M; Kang, EM; Leitman, SF; Little, R; Malech, H; Morgan, RA; Phang, S; Tisdale, JF | 1 |
| Appelbaum, FR | 1 |
| Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN | 1 |
7 review(s) available for fludarabine and Acute Disease
| Article | Year |
|---|---|
Purine nucleoside analogues in the treatment of myleoid leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Use of fludarabine in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Lymphocyte Depletion; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias.
Topics: Acute Disease; Animals; Antineoplastic Agents; DNA Replication; Humans; Leukemia; Leukemia, Experimental; Mice; Vidarabine | 1994 |
New chemotherapeutic agents in acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotoxins; Leukemia, Myeloid; Oligonucleotides, Antisense; Retinoids; Vidarabine | 1996 |
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine | 2001 |
48 trial(s) available for fludarabine and Acute Disease
| Article | Year |
|---|---|
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat | 2022 |
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.
Topics: Acute Disease; Adult; Alemtuzumab; Clinical Trials, Phase II as Topic; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Whole-Body Irradiation | 2023 |
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine | 2020 |
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
Topics: Acute Disease; Adolescent; Adult; Aged; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine | 2017 |
Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Infant; Leukemia; Male; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Infant; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2019 |
Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy.
Topics: Acute Disease; Adult; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2019 |
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Child; Child, Preschool; Coculture Techniques; Combined Modality Therapy; Cyclophosphamide; Diphtheria Toxin; Female; Humans; Interleukin-2; K562 Cells; Killer Cells, Natural; Leukemia, Myeloid; Lymphocyte Depletion; Male; Middle Aged; Recombinant Fusion Proteins; Remission Induction; T-Lymphocytes, Regulatory; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Pilot Projects; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2014 |
Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Topics: Acute Disease; Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Melphalan; Myeloablative Agonists; Neutropenia; Prospective Studies; Risk; Siblings; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine | 2016 |
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antibodies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Leukemia, Myeloid; Leukocyte Common Antigens; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Analysis; Survival Rate; Tissue Distribution; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2009 |
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2010 |
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Topics: Abnormal Karyotype; Acute Disease; Adolescent; Adult; Amsacrine; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cyclophosphamide; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2012 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sex Factors; Societies, Medical; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine | 2013 |
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Vidarabine | 2002 |
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Mycophenolic Acid; Radiotherapy, Adjuvant; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Platelet Count; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Vidarabine | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine | 2004 |
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2005 |
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Topics: Acute Disease; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Siblings; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2005 |
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2005 |
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
Topics: Acute Disease; Adult; Chimerism; Cyclophosphamide; Disease-Free Survival; Female; Fertility; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Vidarabine | 2007 |
FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 1994 |
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Drug Resistance, Neoplasm; Female; Hemorrhage; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Remission Induction; Sepsis; Treatment Failure; Vidarabine | 1996 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retreatment; Risk Factors; Survival Rate; Transplantation, Autologous; Vidarabine | 1998 |
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine | 1999 |
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Sex Factors; Vidarabine | 2001 |
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Survival Rate; Vidarabine | 2001 |
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Pilot Projects; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine | 2001 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Humans; Leukemia; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasms; Pneumonia; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2001 |
82 other study(ies) available for fludarabine and Acute Disease
| Article | Year |
|---|---|
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2023 |
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Bone Marrow; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Whole-Body Irradiation | 2023 |
Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2023 |
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2023 |
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning | 2023 |
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2020 |
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Disease; Dermatomycoses; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Genitalis; Humans; Induction Chemotherapy; Malassezia; Male; Melphalan; Middle Aged; Morocco; Prospective Studies; Skin Diseases; Skin Diseases, Infectious; Vidarabine; Young Adult | 2021 |
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood.
Topics: Acute Disease; Adolescent; Adult; Alopecia; Busulfan; Child; Child, Preschool; Cross-Sectional Studies; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Risk Factors; Transplantation Conditioning; Vidarabine | 2017 |
Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report.
Topics: Acute Disease; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Crohn Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Transplantation Conditioning; Vidarabine | 2013 |
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Graft vs Host Disease; Humans; Male; Melphalan; Methotrexate; Middle Aged; Vidarabine; Young Adult | 2014 |
Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.
Topics: Acute Disease; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Prognosis; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine | 2014 |
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Mucopolysaccharidoses; Myeloablative Agonists; Neurodegenerative Diseases; Practice Guidelines as Topic; Prognosis; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Living Donors; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Recurrence; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Child; Chronic Disease; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemotherapy, Adjuvant; Dasatinib; Humans; Immunosuppressive Agents; Leukemia; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Remission Induction; Vidarabine; Young Adult | 2010 |
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chronic Disease; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Living Donors; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID.
Topics: Acute Disease; Antineoplastic Agents; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Female; Fetal Blood; Graft vs Host Disease; Histocompatibility Testing; Humans; Infant; Lung Diseases, Fungal; Male; Pneumonia, Bacterial; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; X-Linked Combined Immunodeficiency Diseases | 2011 |
Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Flow Cytometry; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Myeloid; Leukocytes, Mononuclear; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Thymus Gland; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Infections; Kaplan-Meier Estimate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Mouth Diseases; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Haploidentical stem cell transplantation for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Survival; Haplotypes; Histocompatibility; Humans; Killer Cells, Natural; Leukemia; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |
Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Siblings; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2003 |
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 3; Caspases; Cytarabine; Daunorubicin; Drug Interactions; Humans; Leukemia, Myeloid; Membrane Glycoproteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Disease Progression; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 2003 |
Fludarabine-related myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Flow Cytometry; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Vidarabine | 2003 |
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine | 2004 |
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infection Control; Infections; Leukemia, Myeloid; Male; Middle Aged; Mycophenolic Acid; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Tumor Cells, Cultured; Vidarabine | 2004 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Bone Marrow; Chromosomes, Human, Pair 7; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Monosomy; Neoplasms, Second Primary; Vidarabine | 2005 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Vidarabine | 2006 |
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Stem Cell Transplantation; Vidarabine | 2006 |
High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematologic Neoplasms; Humans; Leukemia; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
Central line-related bacteraemia due to Roseomonas mucosa in a neutropenic patient with acute myeloid leukaemia in Piraeus, Greece.
Topics: Acute Disease; Adult; Amikacin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bacteremia; Base Sequence; Catheterization, Central Venous; Cytarabine; Humans; Leukemia, Myeloid; Male; Methylobacteriaceae; Molecular Sequence Data; Neutropenia; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; RNA, Bacterial; RNA, Ribosomal, 16S; Vidarabine | 2006 |
Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
Topics: Acute Disease; Antifungal Agents; Cause of Death; Chronic Disease; Cyclosporine; Cytomegalovirus Infections; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Mycoses; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine | 2006 |
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Reoperation; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chimerism; Chronic Disease; Cohort Studies; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Injections, Intravenous; Lymphocyte Transfusion; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chi-Square Distribution; Disease-Free Survival; Drug Resistance, Multiple; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Phenotype; Prognosis; Remission Induction; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Vidarabine | 2007 |
Improved outcome after relapse in children with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Recurrence; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate; Sweden; Treatment Outcome; Vidarabine | 2007 |
Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Blast Crisis; Chimera; Cord Blood Stem Cell Transplantation; Disease Progression; Fatal Outcome; Female; Graft Rejection; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Immunity, Maternally-Acquired; Isoantigens; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine | 2007 |
[Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies].
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Myeloablative Agonists; Risk; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; DNA-Binding Proteins; Female; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Rituximab; Transcriptional Elongation Factors; Translocation, Genetic; Vidarabine | 2007 |
Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine | 2008 |
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
Topics: Acute Disease; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine | 2008 |
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Vidarabine | 2008 |
Acute leukemia complicating bone marrow hypoplasia in an adult with Shwachman's syndrome.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Neutropenia; Pancreatic Diseases; Syndrome; Vidarabine | 1993 |
Secondary neoplasms in two patients treated with purine analogues.
Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Fatal Outcome; Female; Humans; Leukemia, Prolymphocytic; Tumor Lysis Syndrome; Vidarabine | 1993 |
Fludarabine-induced tumour lysis in low-grade non-Hodgkin's lymphoma.
Topics: Acute Disease; Aged; Humans; Lymphoma, Non-Hodgkin; Male; Renal Dialysis; Tumor Lysis Syndrome; Vidarabine | 1997 |
Bayesian interim analysis of phase II cancer clinical trials.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Models, Statistical; Research Design; Vidarabine | 1997 |
Quantification of CMV viraemia in a case of transfusion-related graft-versus-host disease associated with purine analogue treatment.
Topics: Acute Disease; Adult; Antineoplastic Agents; Cytomegalovirus Infections; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Leukemia, Myeloid; Lymphopenia; T-Lymphocytes; Transfusion Reaction; Vidarabine; Viremia | 1997 |
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine | 1997 |
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Risk Factors; Time Factors; Vidarabine | 1998 |
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Time Factors; Vidarabine | 1997 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Vidarabine | 1999 |
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine | 1999 |
Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.
Topics: Acute Disease; Adenosine Deaminase Inhibitors; Antimetabolites, Antineoplastic; Calcitriol; Cell Differentiation; Cladribine; Deoxyadenosines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Monocytes; Neoplasm Proteins; Neoplastic Stem Cells; Pentostatin; Tretinoin; Tumor Cells, Cultured; U937 Cells; Vidarabine | 2000 |
Fludarabine containing regimen followed by autologous peripheral blood stem cell transplantation in unselected patients with acute myeloid leukemia: a single center experience.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2000 |
Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Vidarabine | 1999 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Topotecan; Vidarabine | 2001 |
Reactivation of hepatitis B virus infection during cytotoxic chemotherapy.
Topics: Acute Disease; Aged; Antineoplastic Agents; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 2001 |
Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine | 2001 |
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leukemia, Myeloid; Lymphoma; Neoplasms, Multiple Primary; Remission Induction; Vidarabine | 2001 |
Acute left ventricular failure following melphalan and fludarabine conditioning.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Homologous; Ventricular Dysfunction, Left; Vidarabine | 2001 |
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Cyclophosphamide; Cyclosporine; Feasibility Studies; Ganciclovir; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infection Control; Leukemia, Myeloid; Prednisone; Premedication; Recurrence; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine; Viral Load | 2002 |
Hematopoietic cell transplantation beyond first remission.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Nuclear Family; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 1992 |